Call +49 6221 8278-0

PROGEN - passion for research

close×

WB with anti-Keratin K19 antibody (Cat. No. 61029, 1:100), MCF7 whole cell lysate (5-10 µg) Zoom

WB with anti-Keratin K19 antibody (Cat. No. 61029, 1:100), MCF7 whole cell lysate (5-10 µg)

anti-Keratin K19, Ks19.2 (Z105.6) + positive western blot control

The set provides anti-Keratin K19, Ks19.2 (Z105.6) antibody and associated western blot control - positively tested MCF7 cell lysate.
The set contains enough western blot control to perform 5 western blots.
The anti-Keratin K19 antibody represents an excellent marker to discriminate glandular epithelial carcinoma from those of different origin. No reaction with hepatocellular carcinoma.

application_confirmed highly_published external_validation
Cat. No.: 61029-WBC
Quantity:  50 µg anti-Keratin K19 + 50 µg western blot control

 

Cat. No. Product Name Reactivity Application
61029 anti-Keratin K19 mouse monoclonal, Ks19.2 (Z105.6), lyophilized, purified bovine, human, rabbit, rat ELISA, ICC/IF, IHC, WB
64008 Positive western blot control: anti-Keratin K19 antibody WB

Price as configured: €231.00

Excl. Tax, excl. Shipping Cost

Call us now for more information on our products: +49 6221 8278-0

Any more questions?
PRODUCT REQUEST

Product description

Host mouse
Antibody Type monoclonal
Isotype IgG2b
Clone Ks 19.2 (Z105.6) (also published as BM 19.21, MAK 19.21)
Immunogen Keratin K19 of Mr 40 000; from cultured human MCF-7 cells
Purification cell culture lysate, protein A affinity chromatography
Conjugate unconjugated
Formulation antibody: lyophilized; reconstitute in 1 ml dist. water (final solution contains 0.09 % sodium azide, 0.5% BSA in PBS buffer, pH 7.4); western blot control: lyophilized, reconstitute in 50 µL 1 x SDS buffer (lysis buffer composition: PBS + Pefablock)
Storage antibody: short term at 2 – 8 °C; long term in aliquots at - 20 °C; western blot control: lyophilized at 2-8°C, reconstituted at -20°C; avoid freeze/ thaw cycles for both components
Tested species reactivity bovine, human, rabbit, rat ((negative with mouse, woodchuck, chicken, xenopus))
Intended use research use only

Applications

Tested applications Tested dilutions
ELISA anti-Keratin K19: assay dependent
Immunocytochemistry (ICC)/ Immunofluorescence (IF) anti-Keratin K19: assay dependent
Immunohistochemistry (IHC) - frozen anti-Keratin K19: 1:10 -1:50
Immunohistochemistry (IHC) - paraffin anti-Keratin K19: 1:10 -1:50 (microwave treatment recommended)
Western Blot (WB) anti-Keratin K19: 1:50 - 1:500; western blot control: 5-10 µg total protein per lane

Background

Details

anti-Keratin K19 antibody:
Ks 19.2 represents an excellent marker to discriminate glandular epithelial carcinoma from those of different origin. No reaction with hepatocellular carcinoma! Polypeptide Reacting: Mr 40 000 polypeptide (keratin K19; formerly also designated cytokeratin 19) of human glandular epithelia. The epitope has been localized on aa. 352-368 (VRADSERQNQEYQRLMD) of the α-helical fragment.
Tumors specifically detected: All tested adenocarcinoma; cholangio carcinoma of liver; renal cell carcinoma; transitional cell carcinoma of the bladder; ovary carcinoma; squamous cell carcinoma of cervix, bronchus and lung (intermediate type); mesothelioma; carcinoid tumor of bronchus; breast carcinoma; thymoma.
Reactivity on cultured cell lines: MCF-7

Positive western blot control:
Whole Cell Lysate from MCF7 human breast adenocarcinoma cell line.
MCF7 whole cell lysate was prepared by homogenization in PBS containing Pefablock.
Protein concentration was determined using Bradford assay.

Set content:
Cat. No. 61029, anti-Keratin K19 mouse monoclonal, Ks19.2 (Z105.6), lyophilized, purified
Cat. No. 64008, Positive western blot control: anti-Keratin K19 antibody

Reference

Reference

PublicationSpeciesApplication
Sawitza, I., Kordes, C., Götze, S., Herebian, D. & Häussinger, D. Bile acids induce hepatic differentiation of mesenchymal stem cells. Sci. Rep. 5, (2015). rat ICC-IF
Langbein, L. et al. Characterization of a Novel Human Type II Epithelial Keratin K1b, Specifically Expressed in Eccrine Sweat Glands. J. Invest. Dermatol. 125, 428–444 (2005). human IHC (frozen)
Höchtlen-Vollmar, W. et al. Occult epithelial tumor cells detected in bone marrow by an enzyme immunoassay specific for cytokeratin 19. Int. J. cancer 70, 396–400 (1997). human ELISA
Dittadi, R. et al. Standardization of assay for cytokeratin-related tumor marker CYFRA21.1 in urine samples. Clin. Chem. 42, 1634–8 (1996). human ELISA
Petersen, G., Song, D., Hügle-Dörr, B., Oldenburg, I. & Bautz, E. K. Mapping of linear epitopes recognized by monoclonal antibodies with gene-fragment phage display libraries. Mol. Gen. Genet. MGG 249, 425–31 (1995). epitope mapping
Van Der Gaast ’, A. et al. Evaluation of a new tumour marker in patients with non-small-cell lung cancer: Cyfra 21.1. Br. J. Cancer 69, 525–528 (1994). human ELISA
Sugama, Y. et al. Clinical usefulness of CYFRA assay in diagnosing lung cancer: measurement of serum cytokeratin fragment. Jpn. J. Cancer Res. 85, 1178–84 (1994). human ELISA
Grenier, J. et al. Cyfra 21-1, a new marker of lung cancer. Nucl. Med. Biol. 21, 471–476 (1994). human ELISA
Möbus, V. J. et al. Establishment of new ovarian and colon carcinoma cell lines: differentiation is only possible by cytokeratin analysis. Br. J. Cancer 69, 422–428 (1994). human ICC-IF
Moll, R. et al. The human gene encoding cytokeratin 20 and its expression during fetal development and in gastrointestinal carcinomas. Differentiation. 53, 75–93 (1993). human IHC (frozen)
Pujol, J. L. et al. Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res. 53, 61–6 (1993). human ELISA
Stieber, P. et al. CYFRA 21-1. A new marker in lung cancer. Cancer 72, 707–13 (1993). human ELISA
Moll, I. & Moll, R. Comparative cytokeratin analysis of sweat gland ducts and eccrine poromas. Arch. Dermatol. Res. 283, 300–9 (1991). human IHC (frozen)
Bader, B. L. & Franke, W. W. Cell type-specific and efficient synthesis of human cytokeratin 19 in transgenic mice. Differentiation. 45, 109–18 (1990). human IHC (frozen)
Bosch, F. X. et al. Extensive changes in cytokeratin expression patterns in pathologically affected human gingiva. Virchows Arch. B. Cell Pathol. Incl. Mol. Pathol. 58, 59–77 (1989). human IHC (frozen)
Moll, I., Heid, H. & Moll, R. Cytokeratin analysis of pilomatrixoma: changes in cytokeratin-type expression during differentiation. J. Invest. Dermatol. 91, 251–7 (1988). human IHC (frozen)
Heid, H. W., Moll, I. & Franke, W. W. Patterns of expression of trichocytic and epithelial cytokeratins in mammalian tissues. II. Differentiation. 37, 215–30 (1988). human IHC (frozen)
Heid, H. W., Moll, I. & Franke, W. W. Patterns of expression of trichocytic and epithelial cytokeratins in mammalian tissues. I. Human and bovine hair follicles. Differentiation. 37, 137–57 (1988). human IHC (frozen)
Dockhorn-Dworniczak, B. et al. Patterns of expression of cytoskeletal proteins in human thyroid gland and thyroid carcinomas. Differentiation. 35, 53–71 (1987). human IHC (frozen)

Material safety data sheet

Please complete the form below to request a material safety data sheet

Personal Info

* Required Fields

Product Request

Personal Info

* Required Fields